Aeon Respire
Biopharmaceutical company developing an inhaled dry powder therapy (AR-001) based on niclosamide that targets TMEM16 ion channels for obstructive and infectious respiratory diseases. Work includes particle engineering for lung delivery using supercritical precipitation, preclinical IND-enabling studies and pharmacokinetic evaluation, and development of a capsule-based dry powder inhaler drug-device combination. Primary clinical focus areas include severe asthma, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, lung infections, COPD and cystic fibrosis.
Industries
Nr. of Employees
small (1-50)
Aeon Respire
Newbury Park, California, United States, North America
Products
AR-001
A dry powder inhalation formulation of niclosamide optimized for capsule-based DPI delivery to the lungs; being evaluated in IND-enabling in vivo studies to establish safety and clinical dose ranges.
SCP-1
Inhaled AR-001 for Lung Delivery utilizing Supercritical Precipitation Technology to achieve maximum lung bioavailability, low systemic exposure, and high efficacy potential.
AR-001
A dry powder inhalation formulation of niclosamide optimized for capsule-based DPI delivery to the lungs; being evaluated in IND-enabling in vivo studies to establish safety and clinical dose ranges.
SCP-1
Inhaled AR-001 for Lung Delivery utilizing Supercritical Precipitation Technology to achieve maximum lung bioavailability, low systemic exposure, and high efficacy potential.
Expertise Areas
- Inhalation drug delivery
- Dry powder formulation and particle engineering
- Respiratory disease therapeutics (asthma, COPD, IPF, PAH, CF)
- Ion channel target discovery and pharmacology (TMEM16A)
Key Technologies
- Supercritical precipitation for dry powder particle formation
- Dry powder inhalation (DPI) drug-device combinations
- Aerodynamic particle engineering (0.5–5 μm lung deposition)
- High-throughput screening (HTS) for small molecules
News & Updates
Poster presentation at the American Thoracic Society 2024 International Conference reporting reduced inflammation, bronchoconstriction and airway hyperresponsiveness in a large-animal asthma model.
Report of a pivotal pharmacokinetic (PK) study showing inhaled formulation leads to substantially higher lung exposure compared with oral delivery.
Reference to high-resolution structural studies identifying the niclosamide binding site on TMEM16 proteins.
Announcement of a collaboration and licensing agreement with a particle engineering partner for dry powder formulation development.
Received Phase 2 extension SBIR funding contingent on completion of dry powder formulation milestones during Phase 1.
Report noting TMEM16 inhibitors, including niclosamide, block spike-protein induced syncytia formation and have antiviral activity against SARS-CoV-2.
Poster presentation at the American Thoracic Society 2024 International Conference reporting reduced inflammation, bronchoconstriction and airway hyperresponsiveness in a large-animal asthma model.
Report of a pivotal pharmacokinetic (PK) study showing inhaled formulation leads to substantially higher lung exposure compared with oral delivery.
Reference to high-resolution structural studies identifying the niclosamide binding site on TMEM16 proteins.
Announcement of a collaboration and licensing agreement with a particle engineering partner for dry powder formulation development.
Received Phase 2 extension SBIR funding contingent on completion of dry powder formulation milestones during Phase 1.
Report noting TMEM16 inhibitors, including niclosamide, block spike-protein induced syncytia formation and have antiviral activity against SARS-CoV-2.